New York City Healthcare Venture Capital Report 2018
|
|
- Gloria Bailey
- 6 years ago
- Views:
Transcription
1 New York City Healthcare Venture Capital Report 2018
2 Introduction We are delighted to bring you the first annual New York City Healthcare Venture Capital Report The goal is to provide entrepreneurs, investors, executives, policy makers and all industry stakeholders - with an objective, data-driven look at the importance of the New York market to the healthcare industry. New York City has long been home to a thriving health economy with world-class health systems, global life sciences companies, major payors, top providers, and a tremendous concentration of professional services that support the industry: finance, consulting, law, accounting and media. Over the past decade, New York s healthcare industry has expanded exponentially through private investment and public initiatives. Two areas that have seen particular growth are digital health and life sciences. Accelerators like Startup Health, New York Digital Health Innovation Lab and Digital Health Breakthrough Network and Marketplace have been instrumental in helping ventures get off the ground. Today New York City is #2 in the nation for digital health funding according to Start-Up Health s 2017 Global Digital Health Year End Funding Report. Life sciences also continues to gain momentum with help from the private sector, academia and government. At the end of 2016, Mayor Bill de Blasio announced LifeSciNY, allocating $500 million in investment to establish New York City as the leader in life sciences innovation and R&D. During 2017, Alexandria Launch Labs, BioLabs New York, and New York Stem Cell Foundation brought new lab space and related support services to the city. On tap for 2018: the JLabs launch at the New York Genome Center. With this significant momentum in mind, we are pleased to present the New York City Healthcare Venture Capital Report 2018, which provides an in-depth look at the sectors, investors and start-ups driving this growth. Our findings and analysis show that New York City is an ideal environment in which to launch and build a healthcare company. Our hope is that this report will open your eyes to the breadth and depth of opportunity within New York City. Sincerely, Bunny Ellerin President New York City Health
3 Executive Summary There are approximately 300 venture firms investing in healthcare with headquarters or dedicated offices in New York City. Overall the New York City VC industry remains fairly concentrated. With a hand in 25% of the deals in 2017, the top five VC firms were: 1 Orbimed 2 New Enterprise Associates Healthcare investing reached its highest level yet in 2017 investors deployed $13.8 billion across 412 deals Venrock Deerfield Management Canaan Partners In 2017, 79 New York Citybased healthcare companies received $703 million in funding. The deal CAGR from was an impressive 10% indicating strong growth in New York City s healthcare venture capital (VC) industry. The top 10 Pharmaceutical and Biotech companies accounted for 33% of the total The top 10 Health Technology companies accounted for 25% of the total 3
4 Investors Healthcare Investments by New York Venture Capitalists Investor Deal Trends There are approximately 300 VCs investing in healthcare with operations in NYC. Healthcare investing reached its highest level yet in 2017 investors deployed $13.8 billion across 412 deals. The deal compound annual growth rate (CAGR) from was an impressive 10% indicating strong growth in NYC s healthcare VC industry. Investor Deals and Capital Investments 400 $16, $14, $12, $10,000 $8,000 $6,000 Capital Invested ($M) 100 $4, $2, $0 Deal Count Capital Invested Source: Pitchbook 4
5 Deal Concentration Overall the New York VC industry remains fairly concentrated, with the top 5 VCs having a hand in about 25% of deals The top 30 VCs are involved in almost 60% of the deal volume Various smaller investors that have done fewer deals account for the remaining 40% 100% Deal Flow 100% 90% 80% 70% 60% 56% 50% 42% 40% 34% 30% 23% 20% 10% 0% Top 5 Top 10 Top 15 Top 30 Total New York VC Investors Source: Pitchbook 5
6 TOP 10 NYC Healthcare Venture Capital Investors ( ) INVESTOR # DEALS Orbimed 214 New Enterprise Associates 196 Venrock 91 Deerfield Management 88 Canaan Partners 86 New Leaf Venture Partners 77 Foresite Capital Management 72 Aisling Capital 64 Pfizer Venture Investments 62 Bessemer Venture Partners 47 Source: Pitchbook 6
7 Q&A with Joe Tomaino We asked Joseph Tomaino, Chief Executive Officer, Grassi Healthcare Advisors, LLC, to share his insights on the challenges and opportunities of building a healthcare business in New York City. What are the inherent opportunities of starting and growing a healthcare business in NYC? Innovation in healthcare is in New York City s DNA. For hundreds of years, the City has produced medical leaders and scientific discoveries advancing patient care through its major medical institutions including: Columbia University, Cornell University, NYU/Bellevue, and SUNY Downstate. Because New York is adept both in the science of medicine and how care is delivered, the people and resources needed to develop healthcare businesses are plentiful, and the financial community is comfortable investing in promising enterprises. What are the inherent challenges of starting and growing a business in NYC? New Yok City s size and market complexity present challenges to building a successful business. It requires a diverse and experienced team, coupled with young ideas, to create innovative and transformative solutions. It s about bringing together the right team to create optimal outcomes. We started Grassi Healthcare Advisors, LLC, to provide a team focused on helping healthcare businesses overcome these challenges with innovation and transformation. Which healthcare subsectors are you most excited about over the next 5 years? Why? The biopharma and medical device sectors hold the most potential over the next five years. As science advances and diseases are better understood, transformative approaches to treating them will evolve. For example, the evolution of 3-D printing is an area that warrants close attention as it has the potential to make customized devices more readily available and at lower costs. Services is another area that will grow especially as care continues to move from outside of the four walls of a hospital out into the community, and even to patients homes. 7
8 TOP 10 NYC Pharmaceutical & Biotech Venture Capital Investors ( ) INVESTOR # DEALS Orbimed 151 New Enterprise Associates 94 Foresite Capital Management 59 Pfizer Venture Investments 51 Canaan Partners 49 Deerfield Management 47 Venrock 43 New Leaf Venture Partners 42 Aisling Capital 42 Perceptive Advisors 23 Source: Pitchbook 8
9 TOP 10 NYC Health Technology Venture Capital Investors ( ) INVESTOR # DEALS New Enterprise Associates 26 Venrock 21 New York Digital Health Innovation Lab 19 Oxeon Partners 16 Great Oaks Venture Capital 16 Bessemer Venture Partners 13 New Leaf Venture Partners 12 Activate Venture Partners 12 Orbimed 11 Canaan Partners 11 Source: Pitchbook 9
10 Healthcare Investments in NYC-Based Companies NYC Healthcare Company Trends There are approximately 300 NYC-based healthcare companies that accounted for 510 deals between 2010 and In 2017, 79 healthcare companies received $703 million in funding NYC Company Deals and Capital Investments 90 $ $ $600 Deal Count $500 $400 $300 Capital Raised ($M) 20 $ $ Deal Count Capital Invested Source: Pitchbook 10
11 Q&A with Bill Slattery We asked Bill Slattery, partner at Deerfield Management, to provide his perspective on why New York is an attractive environment for healthcare venture investing. Deerfield is a dedicated healthcare investment firm managing $9 billion dollars across public and private investment funds. The firm invests in many sectors including drugs and biologics, healthcare information technology and services, medical devices and diagnostics. Their mission: to advance healthcare through investment, knowledge, and philanthropy. What s Deerfield s investment philosophy? Deerfield s goal is to identify and invest in discoveries and approaches which generate a meaningful advancement in the field of healthcare. We invest at every stage of discovery maturity, from academic discovery through to the most mature of commercial organizations. stands alone. The healthcare environment is further enhanced because NYC attracts the highest caliber scientists to our institutions. These factors, along with the financial support of state and city government, have given rise to new, local lab facilities, creating the ideal environment for discovery to flourish. Is there a company or investment within New York that you re particularly proud of? Bridge Medicines is a truly unique and powerful company which develops some of the scientific discoveries from three universities, Rockefeller University, Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center, along with partners Deerfield, Takeda Pharmaceuticals and Bay City Capital. Bridge has combined the best of academic research, industrial grade drugging and uniquely positioned experts in the field of drug development. This is the New York investment of which Deerfield is most proud. A unique aspect of Deerfield is its collaborative nature with academia to finance promising discoveries through their translational valley of death. Deerfield has announced agreements with 5 major academic centers. Our goal is to generate a true partnership with joint steering and equally shared economics. What do you think about the New York environment for healthcare? New York has the most productive universities. Whether measured by NIH funding, publication of research, citations or Nobel Prizes, NYC 11
12 TOP 10 IN FINANCINGS IN 2017 NYC Pharmaceutical & Biotech Companies COMPANY Y-mAbs Therapeutics CAPITAL RAISED ($M) $80 Syntimmune $50 BUSINESS Novel antibody therapeutics for oncology targets Advancing novel therapies based on the neonatal Fc receptor IRX Therapeutics $33.23 Novel immunotherapies Cynvec $15 Targeted oncolytic viral immunotherapy Elucida Oncology $10.86 Excision BioTherapeutics TARA Biosystems $9 ILIAD Biotechnologies Novita Pharmaceuticals Target or Clear capabilities of ultra-small C-Dot cancer $10 Advanced gene editing therapeutics $8 $6.46 Clarapath $6.4 Predictive, in vitro human cardiac tissue models Prevention and treatment of disease caused by Bordetella Pertussis Therapeutic drugs for the treatment of cancer Transforming anatomic pathology through high-throughput slide production, imaging and analysis Source: Pitchbook 12
13 TOP 10 IN FINANCINGS IN 2017 NYC Health Technology Companies COMPANY CAPITAL RAISED ($M) BUSINESS AbleTo $36.6 Tech-enabled behavioral health Phreesia $34 Patient intake process Prognos $20.5 AI-enabled predictive analytics Capsule $20 On demand pharmacy Imagen $14.32 AI-enabled medical diagnostics Cohero Health Cedar Health Reveal Ambra Health Virtual Health $13.35 Connected health tools for chronic respiratory disease $12.81 Improving the healthcare financial experience $11.3 Chronic disease detection and management $7.4 Medical data and image management cloud software $7 Population health and care management technologies Source: Pitchbook 13
14 Q&A with Rob Rebak Rob Rebak is CEO of AbleTo, a provider of technology-enabled behavioral health solutions proven to improve patient outcomes and lower healthcare costs. In 2017, AbleTo raised $36.6M. We asked Rob to discuss how their New York City headquarters have driven the business. How has AbleTo benefited from NYC headquarters? While AbleTo s behavioral health platform is used by providers nationwide to treat patients in all 50 states, NYC is at the core of its DNA. We draw from the culture of innovation, resiliency, and inclusion that puts New York atop lists of places to live, work, and play. There is a great pool of experienced talent from the city s digital health industry, and we are also able to attract top technology and data science talent as we tackle some of the most challenging and important problems in the entire healthcare industry, especially concerning the proactive identification, engagement, and successful treatment of millions of people with behavioral health conditions. How has the healthcare community supported your growth? We owe much of our success as a company to the healthcare ecosystem in NYC. Many of our clients have a big presence in the tri-state area, and we are proud to serve their members right here in NYC. Local providers such as Weill Cornell Medical Center refer patients to AbleTo. And we rely on local New York health care institutions, such as the Columbia University School of Social Work, to recruit talented clinical leadership to join our ranks and oversee our network of over 400 therapists and behavioral health coaches across the country. From a CEO s perspective, what are the primary reasons to build a business in NYC? Top challenges? Atop my list as CEO is access to a diverse talent pool specifically for a business like ours - NYC is home to some of the country s best professionals in digital health, technology, data and analytics, marketing and communications, and more. The city also affords companies unparalleled access to capital in a startup-friendly environment, supported by organizations like Startup Health and New York City Health Business Leaders. These same benefits can also create challenges for companies seeking to grow a business in New York. The rich talent pool means that companies must often compete with each other to fill open positions. Access to capital and talent drives costs up, making New York one of the most expensive cities to live and work in. Do you believe NYC location has helped/ hurt your valuation and why? Clients, investors, partners, and employees like and respect our NYC location. The saying is true: if you can make it in New York, you can make it anywhere. 14
15 Conclusion In summary, New York City has claimed its rightful place as a leader in healthcare venture capital investment, yielding innovative, relevant and lucrative companies. Driven by astute investors, a thriving academic community, many professional support firms, and the assistance of local and state government initiatives, the New York City venture capital environment is poised for continued growth and innovation. As the industry grows and evolves, NYCHBL stands at the ready to support, connect and collaborate with today s leaders and tomorrow s visionaries. Authors & Acknowledgements Authors Bunny Ellerin is President and co-founder of NYC Health Business Leaders. She is also Director of the Healthcare and Pharmaceutical Management Program at Columbia Business School. Daniyal Hussain is an MBA student at Columbia Business School. Previously he was an Associate Director in AstraZeneca s immuno-oncology strategy group and prior to that was a life sciences strategy consultant for 6 years. Acknowledgements Joseph Tomaino, Adam Schuman and Joseph Micara of Grassi & Company Bill Slattery and Karen Heidelberger of Deerfield Management Rob Rebak and the team at AbleTo Dr. Bijan Salehizadeh and Kyle Herman of NaviMed Capital Jennifer Newman, marketing consultant Dr. Yin Ho and Anand Gan of NYC Health Business Leaders 15
16 Methodology All data used in the creation of this report was obtained from Pitchbook and covered the period from 01/01/2010 to 12/31/2017. Pitchbook places companies into various healthcare subsectors, which we reviewed and used in our analysis. These include: Healthcare Devices and Supplies Healthcare Services Healthcare Technology Systems Pharmaceuticals and Biotechnology Other Healthcare Two distinct types of analyses were conducted, one from the perspective of healthcare investors located in New York City and one from the perspective of healthcare companies based in New York City. Investor Analysis: The investor analysis tracks the number of healthcare deals each New York City VC has conducted. To compile a complete list of New York City healthcare venture capitalists, we used the Pitchbook database to identify investors within New York City who had done at least one healthcare deal during the period 01/01/2010 to 12/31/2017. Only seed, angel, early-stage and late-stage were considered. We considered an investor to be in New York City if the fund listed New York City as its headquarters OR if the fund had a dedicated office in New York City. Company Analysis: We determined a company was NYC based if (1) the company was classified as healthcare in the Pitchbook database; (2) the company listed NYC as its corporate headquarters; (3) the company received seed, angel, early-stage or late-stage funding during the period 01/01/2010 to 12/31/2017. New York City Health Business Leaders New York City Health Business Leaders is a professional community of 3,000 senior executives who are leading, innovating and driving healthcare forward. It was founded in 2009 by Bunny Ellerin and Dr. Yin Ho. Together they have created a healthcare ecosystem in New York that spans sectors, bringing together the best minds to discuss important issues and spur innovation. It is clear that by connecting the right people leaders, professionals, entrepreneurs, investors we can ignite the right conversations that advance all sides of health. For more information visit or follow
Life Sciences Outlook. New York City 2016
Life Sciences Outlook City 2016 City is emerging as a leading destination for biotech startups and the larger life sciences industry. Investors have committed millions of dollars throughout the city and
More informationFall State of the Industry Report UF SID MARTIN FLORIDA BIODATABASE
Fall 2015 State of the Industry Report UF SID MARTIN FLORIDA BIODATABASE Industry Overview The expansion of Florida s biotech industry remains resilient with an overall growth rate of 92% in the number
More informationUnderstanding Venture Capital
Understanding Venture capitalists believe innovation is the foundation of Michigan s growing economy. As a result, over the last 15 years, the venture capital industry has become a significant driver in
More informationWritten Submission for the Pre-Budget Consultations in Advance of the 2019 Budget By: The Danish Life Sciences Forum
Written Submission for the Pre-Budget Consultations in Advance of the 2019 Budget By: The Danish Life Sciences Forum List of recommendations: Recommendation 1: That the government creates a Life Sciences
More informationNEWS RELEASE. Life sciences companies tout their expertise in India
For Immediate Release 2014MIT0016-000196 Feb. 19, 2014 NEWS RELEASE International Trade and Responsible for the Asia Pacific Strategy and Multiculturalism Life sciences companies tout their expertise in
More informationVenture Capital Search Highlights
Venture Capital Venture funding continued at the strongest pace witnessed over the past decade in 2016, and recruiting the future leaders of the industry s emerging growth companies has never been more
More informationDigital Health Startups A FirstWord ExpertViews Dossier Report
AM PL E PA G ES S A G ES S A FirstWord ExpertViews Dossier Report Published Copyright 2016 Doctor s Guide Publishing Limited All rights reserved. No part of this publication may be reproduced or used in
More informationDriving profitable growth in Greater China. Andy Ho Chief Market Leader Greater China
Driving profitable growth in Greater China Andy Ho Chief Market Leader Greater China Key takeaways China HealthTech market is the 2 nd largest globally and exhibits continued robust growth with significant
More informationMedtech Slowdown. Life sciences venture capital funding lagged behind other industries, declining 10% in 4Q13 and 1% in 2013 over last year
www.pwc.com Medtech Slowdown Life sciences venture capital funding lagged behind other industries, declining 10% in 4Q13 and 1% in 2013 over last year February 2014 2 PwC US venture capital funding for
More informationTrends in Healthcare Investments and Exits 2018
Trends in Healthcare Investments and Exits 208 208 Massachusetts Life Science Innovation Day Clark Hayes Managing Director Life Science/Healthcare Northeast Head of Business Development SVB Corporate Overview
More informationDigital Health. Jiban Khuntia, PhD. Assistant Professor Business School University of Colorado Denver
Digital Health Jiban Khuntia, PhD Assistant Professor Business School University of Colorado Denver Digital Digital usually refers to something using digits, particularly binary digits. Examples: Digital
More informationGlobal Source Ventures, LLC Introduction. Antonius Schuh Managing Partner Stephen Zaniboni Managing Partner
Global Source Ventures, LLC Introduction Antonius Schuh Managing Partner Stephen Zaniboni Managing Partner Introduction to Global Source Ventures GSV provides seed capital to emerging companies with emphasis
More informationWhy Artificial Intelligence will Revolutionize Healthcare including the Behavioral Health Workforce.
Why Artificial Intelligence will Revolutionize Healthcare including the Behavioral Health Workforce. NDBH Conference New Orleans, LA October 28, 2018 A D I S T I N C T I V E L Y D I V E R S I F I E D E
More informationDigital Medical Device Innovation: A Prescription for Business and IT Success
10 September 2018 Digital Medical Device Innovation: A Prescription for Business and IT Success A Digital Transformation is reshaping healthcare. New technology, mobility, and advancements in computing
More informationTRANSLATIONAL SCIENCE
TRANSLATIONAL SCIENCE A Discussion of Best Practices and Unique Models Wednesday January 31, 2018 at The NYSCF Research Institute HRA TRI-STATE REGIONAL MEETING 31 Wednesday January, 2018 AGENDA 8:30 AM
More informationAgenda. Genesys Capital Partners. The Opportunity. Our Approach
MEDT Dinner Presentation September 28, 2005 Agenda Genesys Capital Partners The Opportunity Our Approach Genesys Capital Partners Genesys Capital Partners Successful Track Record Management experience
More informationCASI Pharmaceuticals, Inc.
CASI Pharmaceuticals, Inc. Your Strategic Drug Development Partner in China NASDAQ: CASI WWW.CASIPHARMACEUTIALS.COM Forward Looking Statements This presentation contains forward-looking statements within
More informationMedicines Manufacturing in the UK 2017
Medicines Manufacturing in the UK 2017 Moderator: Magda Papadaki, PhD Head of Manufacturing Innovation The Association of the British Pharmaceutical Industry Medicines Manufacturing Industry Partnership
More informationexecutives are often viewed to better understand the merits of scientific over commercial solutions.
Key Findings The number of new technology transfer licensing agreements earned for every $1 billion of research expenditure has fallen from 115 to 109 between 2004 and. However, the rate of return for
More informationData-Driven Evaluation: The Key to Developing Successful Pharma Partnerships
R&D Solutions for PHARMA & LIFE SCIENCES DRUG DISCOVERY & DEVELOPMENT Data-Driven Evaluation: The Key to Developing Successful Pharma Partnerships Summary For pharmaceutical companies to succeed, it is
More informationDigital Health AI in Life Sciences
Digital Health AI in Life Sciences Surging Digital Health AI Fundraising Drives Transformation in Life Sciences DECEMBER Digital Health AI Accelerates Innovation in Life Science Industry Artificial intelligence
More informationWinners of the McRock IIoT Awards 2018 Announced
June 20, 2018 Winners of the McRock IIoT Awards 2018 Announced Toronto, Ontario--(June 21, 2018) - McRock Capital, a leading venture capital fund manager focused exclusively on the Industrial Internet
More informationPowered by: Norway for Life Science. Photo cover: Christopher Olssøn Design: Fete typer
Powered by: Norway for Life Science Photo cover: Christopher Olssøn Design: Fete typer Content Photo: Istockphoto The Value of the Health Industry 4 The Research Council of Norway 6 Innovation Norway 8
More informationMayo Clinic Ventures. Developing, Commercializing and Funding Mayo Clinic Discoveries. Dan Estes MFMER slide MFMER slide-1
Mayo Clinic Ventures Developing, Commercializing and Funding Mayo Clinic Discoveries Dan Estes 2015 MFMER slide-1 2015 MFMER slide-1 Mayo Clinic Ventures (MCV) primary goals Facilitate the translation
More informationTop 50 Emerging Technologies & Growth Opportunities
Top 50 Emerging Technologies & Growth Opportunities Multi-billion Dollar Technologies Ready to Energize Industries and Transform our World THE VALUE PROPOSITION TechVision s annual Top 50 Emerging Technologies
More informationWOLPERT ASSOCIATES, INC. Strategic Advisory Services Firm Overview
Strategic Advisory Services 2018 Firm Overview Our Foundational Principles Strategic Advice for Biopharmaceutical, Medical Technology and Life Science sectors A Focus on Strategic Thinking in the Context
More informationPerspectives of Innovative Small Companies on the Industry s Prospects for 2012 and Beyond
Perspectives of Innovative Small Companies on the Industry s Prospects for 2012 and Beyond ACI Forum on Structuring, Negotiating and Managing Life Sciences Collaborations and Acquisitions February 28,
More informationNIHR ROADSHOW FOR MEDTECH SMES
MARTIN HUNT, DIRECTOR FOR INVENTION FOR INNOVATION (i4i) PROGRAMME, NATIONAL INSTITUTE FOR HEALTH RESEARCH Martin is Programme Director for i4i, a translational funding programme. i4i aims to support and
More informationFINC915 Venture Lab Participating Firms: FALL 2010
FINC915 Venture Lab Participating Firms: FALL 2010 Please Note: The listed firms will consider candidates. Not all firms will eventually offer a position to students. LOCAL FIRMS: I2A Fund Number of slots:
More information2012 North American Laboratory Researchers Choice: Future Market Leader of Digital PCR Technology Award
2011 South African Data Centre Green Excellence Award in Technology Innovation Cybernest 2012 2012 North American Laboratory Researchers Choice: Future Market Leader of Digital PCR Technology Award 2011
More informationUtrecht Region. A key role in the Netherlands medical technology industry. Why locate your medical technology company in the Utrecht Region?
Utrecht Region A key role in the Netherlands medical technology industry Why locate your medical technology company in the Utrecht Region? The medical technology focus within the region s life sciences
More informationScripps Florida. Accelerating Discoveries, Saving Lives. Presentation to the Urban Land Institute November 4, 2011
Scripps Florida Accelerating Discoveries, Saving Lives Presentation to the Urban Land Institute November 4, 2011 Alex Bruner Associate Vice President, Philanthropy 1921- Founding of the Scripps Metabolic
More informationJURY BOARD BUSINESS/INVESTMENT. Pascal BECACHE Founding President, PBS, Healthcare Industry STRATEGY/BUSINESS
Hosted by : Pascal BECACHE Founding President, PBS, Healthcare Industry INNOLABS IDEAS CONTEST 21 st -22 nd June, Paris JURY BOARD BUSINESS/INVESTMENT Pascal is a seasoned executive with GM and Sales VP
More informationVENTURE-BACKED IPO EXIT ACTIVITY MORE THAN DOUBLES IN Q WITH STRONGEST QUARTER FOR BIOTECH OFFERINGS SINCE 2000
CONTACTS Laura Cruz Tenor Communications for NVCA 1.917.406.7517 laura@tenorcom.com Lauren Herman Thomson Reuters 1.646.223.5985 lauren.herman@thomsonreuters.com VENTURE-BACKED IPO EXIT ACTIVITY MORE THAN
More informationTRIUMF ACCELERATING CANADIAN BUSINESS THROUGH SCIENCE AND INNOVATION Pre-Budget Consultation
Canada s national laboratory for particle and nuclear physics Laboratoire national canadien pour la recherche en physique nucléaire et en physique des particules TRIUMF ACCELERATING CANADIAN BUSINESS THROUGH
More informationUtrecht Region. At the heart of the Netherlands Life Sciences and Health industry. Why locate your life sciences company in the Utrecht Region?
Utrecht Region At the heart of the Netherlands Life Sciences and Health industry Why locate your life sciences company in the Utrecht Region? Utrecht is at the heart of the Netherlands life sciences industry
More informationThe State of Innovation. Orlando Saez
The State of Innovation Orlando Saez Separating fact from myth Myth Illinois is hostile to businesses. Fact Illinois is a good place to do business, and it s getting better everyday. Illinois Economy Highlights
More informationINTEL INNOVATION GENERATION
INTEL INNOVATION GENERATION Overview Intel was founded by inventors, and the company s continued existence depends on innovation. We recognize that the health of local economies including those where our
More informationCeQur establishes Wales subsidiary
FOR IMMEDIATE RELEASE CeQur establishes Wales subsidiary -- Arthurian Life Sciences investment helps bring to market world s first three-day simple insulin infusion device for type 2 diabetes -- LUCERNE,
More informationDOWNLOAD : GLOBAL VENTURE CAPITAL FIRM
DOWNLOAD : GLOBAL VENTURE CAPITAL FIRM FENOX VENTURE CAPITAL â A SILICON VALLEY BASED GLOBAL... portfolio. portfolio fenox-admin 2017-11-09t11:43:28+00:00 all; filter by category; filter by location; exits
More informationPwC Deals $42B. Global Pharma & Life Sciences Deals Insights Q Update
PwC Deals Q3 16 Update Executive summary Global Pharma and Life Sciences (PLS) deal activity declined both in volume and value this quarter compared to the prior quarter and Q3 15. The considerable decrease
More informationExecutive Summary Industry s Responsibility in Promoting Responsible Development and Use:
Executive Summary Artificial Intelligence (AI) is a suite of technologies capable of learning, reasoning, adapting, and performing tasks in ways inspired by the human mind. With access to data and the
More informationA PLATFORM FOR INNOVATION
A PLATFORM FOR INNOVATION June 2017 Innovation is an area of particular focus, both globally and for Canada. It was a core theme in Budget 2017 and it underpins Canada s future economic and social prosperity.
More informationIsrael Venture Capital Investments Report Q3 2017
Israel Venture Capital Investments Report Q3 2017 NOVEMBER 2017 Summary of Israeli Venture Capital Raising Q3/2017 +14% from Q2/2017 Israeli high-tech capital raising summed up to $1.44B @ ALL RIGHTS RESERVED.
More informationPRISME Technical Forum Introduction Accelerating Disruption
PRISME Technical Forum Introduction Accelerating Disruption Presenters: Matthew Rich and Jim Golden Agenda Following the Money: Venture Capital s Influence on Pharma Tech Applications and Possibilities
More informationFlagship Pioneering Fellows Progam
Flagship Pioneering Fellows Progam Where Exceptional Innovators Help Create the Next Disruptive Life Science Startups A Unique Life Science Innovation Enterprise Flagship Pioneering is a unique life science
More informationKate Pretty Lecture Thursday 8 March Pascal Soriot, CEO AstraZeneca. What Science Can Do The Cambridge Cluster at a Pivot Point
Kate Pretty Lecture Thursday 8 March 2018 Pascal Soriot, CEO AstraZeneca What Science Can Do The Cambridge Cluster at a Pivot Point Introduction Thank you for your invitation and warm welcome to Homerton
More informationWhere the brightest scientific minds thrive. IMED Early Talent and Post Doc programmes
Where the brightest scientific minds thrive. IMED Early Talent and Post Doc programmes Scientific innovation is at the heart of everything we do. Scientific innovation is at the heart of our business and
More informationTechnology transfer industry shows gains
Technology transfer industry shows gains in patents filed and granted, university-created startups and commercial products; slippage in federal research funding cited Highlights of AUTM s Canadian Licensing
More informationCVC2.0 Demonstrating Added Value to the Corporate Bottom Line
CVC2.0 Demonstrating Added Value to the Corporate Bottom Line Jaideep Raje Managing Consultant Lux Research June 2, 2016 Agenda CVC1.0 State of the Union So, why change? Reflections on CVC2.0 2 Contents
More informationCapability to Transform Care Delivery
National Healthcare Innovation Summit June 10, 2013 Building a Design Driven Innovation Capability to Transform Care Delivery Barbara Spurrier, MHA Director, Center for Innovation 2011 MFMER 3110267-1
More informationJOHN JACK R. TUPMAN, JR CURRICULUM VITAE
JOHN JACK R. TUPMAN, JR CURRICULUM VITAE September 2018 John R. Tupman, Jr. is a consultant focused on business development and licensing in the life sciences industry. He is currently working as a consultant
More informationIn this first of a series of MVision Insights, we commissioned research from the London Business School into the participation of women in the US
In this first of a series of MVision Insights, we commissioned research from the London Business School into the participation of women in the US venture capital business. Our aim is to stimulate a debate
More informationwww.philadelphiapact.com 2 PACT Founding Supporters Actua AMETEK Ben Franklin Technology Partners Bentley Systems Comcast Business Cozen O'Connor Duane Morris EY Evolve IP Fairmount Partners Fox Rothschild
More informationWinter 2004/05. Shaping Oklahoma s Future Economy. Success Stories: SemGroup, SolArc Technology Yearbook
Winter 2004/05 Shaping Oklahoma s Future Economy Success Stories: SemGroup, SolArc Technology Yearbook By William H. Payne Angel Investor and Entrepreneur-in-Residence at Kauffman Foundation, Kansas City
More informationBayer Inc. Science for a Better Life. Talking with Phil Blake, President, Bayer Inc., HealthCare Representative and Head, Pharmaceuticals Division
Bayer Inc. Science for a Better Life Talking with Phil Blake, President, Bayer Inc., HealthCare Representative and Head, Pharmaceuticals Division Please review your career path to date, leading to your
More informationImagine your future lab. Designed using Virtual Reality and Computer Simulation
Imagine your future lab Designed using Virtual Reality and Computer Simulation Bio At Roche Healthcare Consulting our talented professionals are committed to optimising patient care. Our diverse range
More informationInternational Conference on Pharmaceutical Research and Development June 06-07, 2018 Philadelphia, USA
International Conference on Pharmaceutical Research and Development,, https://research.pharmaceuticalconferences.com Invitation Dear Attendees, We are glad to announce the International Conference on Pharmaceutical
More informationPANEL DISCUSSION & ROUNDTABLES
LIFE SCIENCES & HEALTH CARE EVENT Road to commercialization - Challenges, Opportunities & Successes that lie ahead in the Life Sciences and Healthcare Sectors Life Sciences and Healthcare is one of the
More informationTECHNOLOGY VISION 2017 IN 60 SECONDS
TECHNOLOGY VISION 2017 IN 60 SECONDS GET THE ESSENTIALS THE BIG READ SHORT ON TIME? VIEW HIGHLIGHTS 5 MIN READ VIEW FULL REPORT 45 MIN READ VIEW SHORT REPORT 15 MIN READ OVERVIEW #TECHV1SION2017 2017 TREND
More informationVenture Capital Investment Consortium
Venture Capital Investment Consortium Request for Proposals Question & Answer Information Session: October 4, 2018 RFP Submission Date: November 9, 2018 Our VISION: New York City is the global model for
More informationCatapult Network Summary
Catapult Network Summary 2017 TURNING RESEARCH AND INNOVATION INTO GROWTH Economic impact through turning opportunities into real-world applications The UK s Catapults harness world-class strengths in
More informationADVANCING KNOWLEDGE. FOR CANADA S FUTURE Enabling excellence, building partnerships, connecting research to canadians SSHRC S STRATEGIC PLAN TO 2020
ADVANCING KNOWLEDGE FOR CANADA S FUTURE Enabling excellence, building partnerships, connecting research to canadians SSHRC S STRATEGIC PLAN TO 2020 Social sciences and humanities research addresses critical
More informationFDA Centers of Excellence in Regulatory and Information Sciences
FDA Centers of Excellence in Regulatory and Information Sciences February 26, 2010 Dale Nordenberg, MD novasano HEALTH AND SCIEN Discussion Topics Drivers for evolution in regulatory science Trends in
More informationTechnology and Innovation in the NHS Scottish Health Innovations Ltd
Technology and Innovation in the NHS Scottish Health Innovations Ltd Introduction Scottish Health Innovations Ltd (SHIL) has, since 2002, worked in partnership with NHS Scotland to identify, protect, develop
More informationFlorida Venture Capital Highlights
InternetCoast Florida Innovation Highlights Series Florida Venture Capital Highlights 2013 2017 2017 Florida Investment Activity Best Since 2000 InternetCoast January 2018 Dale Gregory President, InternetCoast
More informationClimate Change Innovation and Technology Framework 2017
Climate Change Innovation and Technology Framework 2017 Advancing Alberta s environmental performance and diversification through investments in innovation and technology Table of Contents 2 Message from
More informationThelander 2016 PRIVATE COMPANY YEAR END MERIT INCREASE PITCHBOOK REPORT. J. Thelander Consulting
Thelander 2016 PRIVATE COMPANY YEAR END MERIT INCREASE PITCHBOOK REPORT J. Thelander Consulting 165 Marlin Mill Valley, CA 94941 jt@jthelander.com jthelander.com +1 415.383.7006 Legal Notice: The Thelander
More informationIVC-MEITAR HIGH-TECH EXITS H1/ 2015 REPORT. IVC-Meitar 2014 Exits Report Prepared by IVC Research Center Ltd.
IVC-MEITAR HIGH-TECH EXITS H1/ 215 REPORT IVC-Meitar 214 Exits Report Prepared by IVC Research Center Ltd. Israeli High-Tech Exit Highlights Exit proceeds in H1/215 reached ¾ of total exits for 214 Average
More informationIntroduction. digitalsupercluster.ca
Introduction digitalsupercluster.ca Government of Canada s Innovation Supercluster Initiative Federal government investing $950MM into superclusters to drive growth, prosperity, jobs and global leadership.
More informationFinal Pitch Competition PROGRAM GUIDE. Wednesday, March 2, 2016 at HIMSS16 VENETIAN - PALAZZO - SANDS EXPO CENTER LEVEL 3 - LIDO 3104 LAS VEGAS, NV
Final Pitch Competition PROGRAM GUIDE Wednesday, March 2, 2016 at HIMSS16 VENETIAN - PALAZZO - SANDS EXPO CENTER LEVEL 3 - LIDO 3104 LAS VEGAS, NV #HITVenture #HIMSS16 1 Presented by: WEDNESDAY, MARCH
More informationMCGILL CENTRE FOR THE CONVERGENCE OF HEALTH AND ECONOMICS (MCCHE)
MCGILL CENTRE FOR THE CONVERGENCE OF HEALTH AND ECONOMICS (MCCHE) Enabling collaboration among business, civil society, government and academia for improved health outcomes and economic benefits The MCCHE
More informationEnabling ICT for. development
Enabling ICT for development Interview with Dr M-H Carolyn Nguyen, who explains why governments need to start thinking seriously about how to leverage ICT for their development goals, and why an appropriate
More informationHealthTech: What does it mean for compliance?
HealthTech: What does it mean for compliance? May 2018 Agenda 11:15 AM 11:30 AM Introduction Kathleen Meriwether, Americas Leader - Life Sciences Fraud Investigation & Dispute Services, EY 11:30 AM 12:15
More informationExperiences of an aspiring young scientist-entrepreneur
Experiences of an aspiring young scientist-entrepreneur Francis W. Hunter Auckland Cancer Society Research Centre Spark Entrepreneurship Challenge Mesopharm Therapeutics, Inc. 5 May 2014 Background Auckland
More informationA Case Study on the Use of Unstructured Data in Healthcare Analytics. Analysis of Images for Diabetic Retinopathy
A Case Study on the Use of Unstructured Data in Healthcare Analytics Analysis of Images for Diabetic Retinopathy A Case Study on the Use of Unstructured Data in Healthcare Analytics: Analysis of Images
More informationWhere does Design add Value in a Tech Start-up? DMI Boston Conference Sept 28th, 2015
Where does Design add Value in a Tech Start-up? DMI Boston Conference Sept 28th, 2015 gulayozkan.com @gulayozkan GEDS is a design and innovation studio that uses design-driven methods to connect organizations
More informationMake an Executive Decision to Fight Cancer.
Make an Executive Decision to Fight Cancer. A Message from President and CEO, Edward J. Benz, Jr., MD President s circle Corporate Leaders Few institutions can match the strength and leadership that Dana-Farber
More informationPublication Date Reporter Pharma Boardroom 24/05/2018 Staff Reporter
Publication Date Reporter Pharma Boardroom 24/05/2018 Staff Reporter Pharma Boardroom An Exclusive Interview with Jonathan Hunt CEO, Syngene International, India. Jonathan Hunt, CEO of Syngene International,
More informationAugust 17, The Testimony of Christopher P. Molineaux President & CEO Pennsylvania Bio
Joint Democratic and Republican House Policy Committee Hearing August 17, 2016 The Testimony of Christopher P. Molineaux President & CEO Pennsylvania Bio Chairman Benninghoff, Chairman Sturla, and members
More informationFinancing Baltimore s Growth: Venture Capital Support for Small Companies
Financing Baltimore s Growth: Venture Capital Support for Small Companies by Mary Miller, Ben Seigel, Mac McComas, and Lee Scrivener October 2018 Executive Summary In 2017, the Johns Hopkins 21st Century
More informationMENTORS REGULATORY AFFAIRS. Christophe AMIEL Head of Medical Device & Digital, Voisin Consulting Life Sciences STRATEGY/BUSINESS
Hosted by : INNOLABS IDEAS CONTEST 21 st -22 nd June, Paris MENTORS REGULATORY AFFAIRS Christophe Amiel is heading the design and operational implementation of international regulatory strategies as Senior
More informationChairman of Trendlines Medical Singapore Todd Dollinger added, We are pleased to work
Singapore government investment arm of SPRING SEEDS Capital backs Trendlines Medical Singapore and Ozi Amanat s K2 Global to collaborate in its SGD100M investment allocation for tech start-ups Misgav,
More informationOmeros Raises More Than $63 Million in Financing
Omeros Raises More Than $63 Million in Financing Seattle, WA February 12, 2007 Omeros today announced that it has raised in excess of $63 million in an oversubscribed Series E equity financing. New investors,
More informationEU s Innovative Medical Technology and EMA s Measures
EU s Innovative Medical Technology and EMA s Measures 27 October 2017 Summit symposium 25-27 October 2017, Kyoto, Japan Presented by Guido Rasi Executive Director, European Medicines Agency (EMA) An agency
More informationNJEN: STATE AND FEDERAL RESOURCES FOR ENTREPRENEURS. April 13, 2016
NJEN: STATE AND FEDERAL RESOURCES FOR ENTREPRENEURS April 13, 2016 New Jersey Economic Development Authority Mission The New Jersey Economic Development Authority (EDA) is an independent State agency that
More informationBrief to the. Senate Standing Committee on Social Affairs, Science and Technology. Dr. Eliot A. Phillipson President and CEO
Brief to the Senate Standing Committee on Social Affairs, Science and Technology Dr. Eliot A. Phillipson President and CEO June 14, 2010 Table of Contents Role of the Canada Foundation for Innovation (CFI)...1
More informationOverview of Venture Equity
Overview of Venture Equity SVB Analytics Report 2017 Written by SVB Analytics: Steve Liu Managing Director sliu@svb.com Sean Lawson Senior Manager slawson2@svb.com Steven Pipp Senior Associate spipp@svb.com
More informationTechnology Leadership Course Descriptions
ENG BE 700 A1 Advanced Biomedical Design and Development (two semesters, eight credits) Significant advances in medical technology require a profound understanding of clinical needs, the engineering skills
More informationHealth Innovations in Horizon 2020: the framework programme for research and innovation ( )
Health Innovations in Horizon 2020: the framework programme for research and innovation (2014-2020) Virginija Dambrauskaite, MD, PhD Scientific Officer, Medical Research Unit, Health Directorate Directorate-General
More informationReinventing Invention: Advancing Collaboration for Sustainable Bioscience R&D
Reinventing Invention: Advancing Collaboration for Sustainable Bioscience R&D John C. Lechleiter, Ph.D. Chairman, President, and Chief Executive Officer Eli Lilly and Company Washington Biotechnology &
More informationGlobal Alzheimer s Association Interactive Network. Imagine GAAIN
Global Alzheimer s Association Interactive Network Imagine the possibilities if any scientist anywhere in the world could easily explore vast interlinked repositories of data on thousands of subjects with
More informationQ&A with Samira Salman
APRIL 2017 VOL. 5 ISSUE 122 R E P O R T Q&A with Samira Salman Founder of Salman Solutions. Principle Series: Family Office Insights sits down with Samira Salman to discuss successful deal structuring
More informationSecurity and Risk Assessment in GDPR: from policy to implementation
Global Data Privacy Security and Risk Assessment in GDPR: from policy to implementation Enisa Workshop Roma - February 8, 2018 Nicola Orlandi Head of Data Privacy Pharma Nicola Orlandi Nicola Orlandi is
More informationDigital Health, Technology and Life Sciences. Skip Fleshman
Digital Health, Technology and Life Sciences Skip Fleshman General Partner skip@assetman.com @SkipFleshman, @AMV Firm Facts AMV invests in early stage startups spanning digital health, technology and life
More informationDaVita HealthCare Partners Inc. (DVA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
DaVita HealthCare Partners Inc. (DVA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile DaVita HealthCare Partners Inc. (DVA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Sector
More informationg~:~: P Holdren ~\k, rjj/1~
July 9, 2015 M-15-16 OF EXECUTIVE DEPARTMENTS AND AGENCIES FROM: g~:~: P Holdren ~\k, rjj/1~ Office of Science a~fechno!o;} ~~~icy SUBJECT: Multi-Agency Science and Technology Priorities for the FY 2017
More informationHealth & Social Care Industrial Innovation
Health & Social Care Industrial Innovation Mr Andrew Fowlie Scottish Government Health Innovations Team SHINE North Sea Region Program 2014 2020 Scotland s Medical Technologies Landscape Imaging Non Imaging
More informationMolecular Pathology. Theme: Exploring the clinical practices and research ideas in the field of molecular Pathology. Molecular Pathology 2019
International Conference on Molecular Pathology July 31-August 01, 2019 Amesterdam, Nertherlands Theme: Exploring the clinical practices and research ideas in the field of molecular Pathology Invitation
More informationMaking lives better every day. This is UCB
Making lives better every day. This is UCB Kristof, living with axial spondyloarthritis Remi, UCB Inspired by patients. Driven by science. We have a shared ambition to transform the lives of people living
More information